SLXN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Silexion Therapeutics Corp (SLXN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's financial performance is weak, with significant losses in net income and EPS. While there is a positive analyst rating and potential future catalysts in regulatory filings, the lack of strong trading signals, neutral insider and hedge fund sentiment, and no recent news or congress trading data make it prudent to hold off on investing in this stock right now.
The MACD is positive and contracting, indicating mild bullish momentum. The RSI is neutral at 54.257, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level of 1.731, with a pivot at 1.605. Overall, the technical indicators do not strongly support a buy signal.
An analyst has initiated coverage with a Buy rating and a $6 price target, citing the company's innovative siRNA platform and potential late-stage clinical development. Regulatory submissions in Israel and Europe are expected in the near future.
The company's financials are weak, with a significant drop in net income (-72.50% YoY) and EPS (-97.99% YoY). There is no recent news, no congress trading data, and hedge fund and insider sentiment are neutral. The stock also has a 60% chance of declining by -1.9% in the next day.
In Q3 2025, the company reported zero revenue growth (0.00% YoY) and a significant decline in net income (-72.50% YoY) and EPS (-97.99% YoY). Gross margin remains at 0, indicating no profitability.
Litchfield Hills analyst Theodore O'Neill initiated coverage with a Buy rating and a $6 price target, highlighting the company's innovative approach to KRAS-driven cancers and upcoming regulatory submissions.
